Donor funds can be made Limited duration of availability **Financial** available for AMR related of donor funds resources activities Identify internal donor fund streaming / better integration of AMR related issues into existing programs Conduct training and Sustaining of IPC and AMR Technical awareness on AMR (IPC, related activities as trained capacity antimicrobial stewardship, staff maybe allocated for other animal health, aquatic animal tasks: (pandemic preparedness, Quality related activities etc). health, food safety etc.) Integrate HAI surveillance with High turnover of trained staff AMR reporting using Infection control nurses and link nurses in health facilities. Each health facility to have an infection control officer (clinician or microbiologist) responsible for AMR and antimicrobial stewardship. Animal health establish national focal point (vet), include IPC, HAI and stewardship component in animal health. Reporting of outbreaks in veterinary facilities etc. Assess laboratory capacity / integrate and support for laboratory component of animal AMR related surveillance/ Food safety: establish antimicrobial residue testing Structures or Establish well defined AMR Sustainability and high human enablers for governance structure, with turn over

implementation



dedicated unit for coordination of AMR related activities and

annual plan



Establish well defined AMR governance structure, with dedicated unit for coordination of AMR related activities and annual plan		
Identify champions at different levels (political, councils, social media, religious etc). TOTs for AMR related education and training (could be the ICN or Infection control Officer at health facility level)	Competing interest from private sector on reporting such as outbreaks etc.	Implementation of NAP AMR activities
Use surveillance data for standard of care and economic case for implementing AMR activities Strengthen monitoring indicators (process and outcome based) for measuring NAP implementation and use for advocacy	Limited data (monitoring and surveillance) shared within and in-between sectors may lead to inconsistent messaging on AMR	The state of the s



Annex 2. Situation analysis of NAPAMR 2017 to 2022 implementation



Table 13: Situation Analysis of NAP AMR 2017-2022 implementation

Strategic Objective	Planned Strategic intervention	Sub-Activities	Target	Status
1. Awareness	1.1: To improve awareness of AMR amongst the general p u b l i c a n d professionals	Conduct KAP Studies on AMR, AMU,(human and animal) environmental relationships in different target groups (school students and teachers, general public, policy makers, clinicians, pharmacists, nursing staff, farmers in poultry/goat/aquaculture farming, pet owners and pet shop owners)	2017	2
		Design evidence-based communication campaigns with accurate and relevant messages targeting priority groups	2018	2
		Roll out communication campaigns on AMR	2017-2018	2
		Incorporate AMR and related topics in school grade 1-12 school curricula. Limited scale testing of revised curriculum along with regular audit of courses will be conducted before planning a nationwide scale up by 2022	2019	3
		Evaluate communication campaigns followed by nationwide implementation. Pilot campaigns will be evaluated in 2019. This will be followed by nationwide scale up and scale out of awareness campaigns in 2019 with regular monitoring and evaluation		2
		Conduct KAP Studies to assess gaps in knowledge on AMR, hygiene & IPC, environmental relationships in professional groups	2017-2018	2
1.2 Improve knowledge of AMR and related topics in professionals through profession alleducation and training deployed at national scale	Revise and roll out professional development courses of human and animal health, the food industry and agriculture sectors to include topics on AMR and related issues. Roll out of courses will be done on a limited scale along with concurrent regular audits followed by nationwide scale up.	2019-2020	1	
	education and training deployed at	Revise undergraduate and postgraduate curricula in human and animal health, Food industry and Agriculture sector to include topics on AMR and related issues. Limited scale testing of revised curriculum along with regular audit of courses will be conducted before planning a nationwide scale up in next phase of NAP	2020-2022	1

Strategio Objective	Planned Strategic intervention	Sub-Activities	Target	Status
2. Surveillance	2.1 Establish a national coordination	Establish AMR Surveillance Coordination Unit, define mandates, terms of reference and identify a focal point. The ASCU will be located in the MFDA	2017	1
of AMR	structure for surveillance of AMR	Develop a One Health AMR guidelines and plan for surveillance in humans, animal and food industry based on international standards and guidelines	2017-2018	1
		Enlist priority pathogens and antimicrobials for surveillance in human, animal and food industry	2017-2018	3
		Assess and inventory of resources for sentinel environmental surveillance (ASCU with EPA and Ministry of Environment)		1
		Conduct trainings on AMR surveillance for surveillance staff		1
		Develop an integrated human and animal IT platform for AMR surveillance reporting. WHONET platform will be implemented for epidemiological and laboratory AMR surveillance data entry, storage and transmission in human clinical and food testing labs		i
		Implement National AMR Surveillance Program including sentinel environmental surveillance of antimicrobial resistance organisms and antimicrobial residues. IGMH, Regional Hospitals and Atoll Hospitals with existing Bacterial AST facility will be targeted in the pilot phase. Additionally, ADK Hospital from private sector will be included as a surveillance site. For animal surveillance selected poultry commercial, goat farms and aquaculture farms will be recruited and specimens submitted to NHL	2019-2022	2
		Establish formal linkage of National AMR Surveillance Programme and WHO GLASS	2021-2022	2
		Conduct formal assessment of National AMR Surveillance Program		1
	2.2: Build laboratory capacity under the leadership of a National Referral Laboratory (NRL) to	Identify National Reference Laboratory (NRL) for AMR Surveillance in Maldives with expertise in methods for confirming and characterising specific pathogens, performing susceptibility testing, organising quality assurance and participating in external quality assurance schemes (EQARDS). The Microbiology Laboratory at IGMH will be identified as NRL		2
	produce high-quality microbiological data for patient and food-safety management and support surveillance activities.	Identify participating laboratories of National AMR Surveillance Network that are capable of identifying target pathogens and perform susceptibility testing (centres as per section 2.1)		2
	2.3 Develop a multi- centric surveillance system on the national scale to provide early warning of emerging resistance and monitoring of secular trends at national and sub-national levels.	Establish a network of agencies for AMR hazard and risk assessment	2017-2019	1

Strategic Objective	Planned Strategic intervention	Sub-Activities	Target	Status
		Develop and disseminate guidelines and national standards for systematic collection, sharing, and assessment of AMR hazard events		1
		Enlist priority pathogens and AMAs for AMR hazard risk assessment		2
		Conduct surveys to establish baseline estimates and trends of AMR to determine risks and establish thresholds for alerts and action systems		1
		Establish a central library or database on AMR risk information	2020-2021	2
		Conduct and communicate comprehensive real time analysis of AMR hazards in the human, animal, food industry and environment sector to inform programme planning and action	2021-2022	î
3. Hygiene, 3.1: To establish a national infection prevention and control	Evaluate existing IPC, and Biosecurity guidelines. Develop a national IPC policy, mandating the creation and harmonization of National IPC Programmes in healthcare facilities and food production systems (poultry, goat farms, aquaculture)		2	
(IPC)	(IPC) programme through full implementation and compliance with the IPC	Develop IPC guidelines with implementation for infection prevention and control in all health care settings (hospital and ambulatory) in human sector; IPC/biosecurity in animal health facilities (hospital and ambulatory), vaccination, and biosecurity in the farm to fork chain		2
guidelines within healthcare settings, animal husbandry systems, fisheries and the food chain	Identify target groups to be trained in IPC from different sectors and at different levels		2	
	Train target groups in different sectors in IP		2	
	Roll out IPC program in human health, animal health and food industry		2	
		Review existing professional curricula for content on IPC and develop training modules for their incorporation into professional courses		2
		Assess National IPC Programme and recommend Nationwide scale up in human, animal healthcare facilities, food production systems.		2



Strategic Objective	Planned Strategic intervention	Sub-Activities	Target	Status
	3.2: Decrease	Develop guidelines for Hospital Associated Infection (HAI) Surveillance	2017-2018	3
	Infection (HAI) and associated AMR	Implement a pilot scale on HAI surveillance in select public and private healthcare facilities	2019-2022	3
	(Human Health)	Integrate HAI surveillance network into National AMR surveillance network; Conduct formal assessment of HAI Surveillance network for nationwide scale-up	2022	i
	3.3: To limit the development and	Review and evaluate the existing national campaigns on water, sanitation & hygiene (WASH), food safety, and vaccination in humans and animals	2017	2
	spread of AMR outside health settings	Implement formal campaigns for sanitation and hygiene in human, animal, food animal production sector	2018	2
		Evaluate existing vaccination programme in human and animal sectors for their effectiveness and coverage		3 Huma
		Evaluate existing vaccination programme in human and animal sectors for their effectiveness and coverage		1 Anima
		Review and revise undergraduate and post graduate curricula to include course content related to water, sanitation, hygiene and food handling	2018-2019	2

Evaluate campaigns on hygiene and sanitation

2

2019

practices



Strategic Objective	Planned Strategic intervention	Sub-Activities	Target	Status
4: Optimise Use of	4.1: Establish a national	Develop a national AMR containment policy and organizational framework within the charter of the Policy	2017-2019	3
Medicines	Antimicrobial Antimicrobial Medicines Stewardship Programme on a	Formulate a regulatory framework for control of antimicrobial substances in human, animal sectors and food industry		2
	national scale to improve and measure	Develop standard treatment guidelines (STGs) for antimicrobial use in human and animal healthcare and food industry		2
	of antimicrobials	Conduct surveys to characterize institutional Antimicrobial Stewardship Programmes (AMSP)		2
		Develop evidence-based guidelines for a National AMSP		3
		Implement AMR containment policy for control of human and veterinary use of antimicrobial substances in human and animal health care, ambulatory and community settings and food industry	2018-2022	2
	4.2: Regulate post-marketing quality of drugs to	Formulate a National Drug Policy with special reference to AMAs and AMR applicable to human, animal health, and food industry. Introduce legislation and regulations on AMAs for veterinary use.	2017	2
	ensure access to safe and quality antibiotics	Strengthen existing National Drug Regulatory Authority and establish additional regulatory frameworks. Human resource and technical capacity of National Health Laboratory of MFDA will be strengthened to establish systematic surveillance of quality of imported drugs and food at points of entry	2017-2019	3
		as well as post marketing surveillance of drugs and food. MFDA will cover drugs used in human health, extend similar regulatory framework to import medicines for animal health, aquaculture and food production		1
		Establish import procurement systems favourable to regulatory compliance		1
		Establish a system for the coordination and collation of data on drug quality		3
M		Establish and implement an institutional network with the capacity for quality control and enforcement of regulatory provisions for antimicrobial agents or APIs	2017 -2022	2
(0)	2/	Conduct independent periodic surveys to estimate the extent of OTC and inappropriate sales of antibiotics and APIs		3



as well as post marketing surveillance of drugs and food. MFDA will cover drugs used in human health, extend similar regulatory framework to import medicines for animal health, aquaculture and food production		4
Establish import procurement systems favourable to regulatory compliance		1
Establish a system for the coordination and collation of data on drug quality		3
Establish and implement an institutional network with the capacity for quality control and enforcement of regulatory provisions for antimicrobial agents or APIs	17 -2022	2
Conduct independent periodic surveys to estimate the extent of OTC and inappropriate sales of antibiotics and APIs		3



Strategic Objective	Planned Strategic intervention	Sub-Activities	Target	Status
	4.3: Establish mechanisms to monitor antimicrobial	Establish AMU Surveillance coordination structure Design an AMU and residue monitoring program in humans, animals and food	2017	1 2 AMU
	usage on a national	industry; develop guidelines to implement residue testing	2018	humans
	scale to inform interventions to	Implement AMU surveillance and residue testing	2019-2022	2 AMU only
	reduce overuse and promote prudent use of antimicrobial substances	Conduct integrated analysis of AMU, AMR and residue surveillance data to guide programme planning		2 AMU only
5: (Economic) Case For	To promote sustainable	Create an inventory of relevant networks, initiatives, institutions and experts involved in AMR research	2017-2018	2
Sustainable Investments And Increase	investment in new medicines, diagnostic tools, vaccines and	Develop a Strategic research agenda, with systematically prioritised research areas and knowledge gaps in the field of AMR		î
Investments In New	other interventions by developing a	Develop a National AMR Research Policy	2017-2018	1
Medicines,	strategic research	Establish a multi-stakeholder platform to guide AMR research and innovation	2018-2019	1
Diagnostic Tools, Vaccines And Other	agenda and national research policy	Document and disseminate to different stakeholders, evidence on AMR and related issues for policy and programme intervention	2020-2022	ì
To Reduce Antimicrobial Use				



Annex 3. Tripartite AMR Country Self-Assessment Survey 2022 Maldives (TrACSS)- AMR governance component

Table 14: Tripartite AMR Country Self assessment Survey 2022 Maldives (TrACSS)- AMR governance component

NAP AN	AR gov	ernance	
Summary of multisector indicators	Summary of multisector indicators		
Formulated multisector coordination mechanism	NO	Human health	YES
Developed NAP AMR	YES	Terrestrial animal health	YES
Implementing NAP AMR	YES	Aquatic animal heath	NO
Country in the process of revising NAP AMR or developing new one	YES	Plant health	YES
Country has a monitoring and evaluation plan for AMR	NO	Food production	NO
Country has government supported nationwide awareness campaigns	NO	Food safety	YES
Country has established or started the implementation of an integrated surveillance system for AMR	NO	Environment	YES

Annex 4: Facility level data collection tool for IPC and Antimicrobial Stewardship Program (AMSP)

Annex 4: Facility level data collection tool for IPC and Antimicrobial Stewardship Program (AMSP)

Assessment on Facility level (Infection Prevention and Control (IPC) and Antimicrobial Stewardship (AMS) program (World Health 2018, World Health Organization 2018, Purva, Randeep et al. 2019)

Name of t	the healthcare facility	y:		
Total inpatie	ent bed number			
Services pro	ovided by the facility:			
	• OPD			
	• IPD			
	Surgical			
	Day care (di	alysis etc):		
Date of filling	g the assessment form	dd /mm /year		
Staff wh	o took part in fillir	ng the form (Put the n	nain responsible p	erson as number one)
	Name	Designation	Job role	comment
1				
2				
3				
4				
200				THE TOTAL PROPERTY CONT.
771	ublished studies on IPC	, HAI or AMR from the facil	ity and/from Maldives.	Please provide link below
1.				
2.				
3.				
4.				

PART 1: FACILITY LEVEL IPC PROGRAM

PART 1: FACILITY LEVEL IPC PROGRAM

Table 15: Facility level IPC program assessment tool (adapted from WHO)

Question	Answer	Score
Do you have an IPC programme?	□ No	0
Choose one answer	☐ Yes, without clearly defined objectives	5
	☐ Yes, with clearly defined objectives and annual activity plan	10
2. Is the IPC programme supported by an IPC team comprising	□ No.	0
of IPC professionals? ⁴ Choose one answer	☐ Not a team, citly an IPC focal person	5
	□ ves	10
3. Does the IPC team have at least one full-time IPC professional	☐ No IPC professional available	D
or equivalent (nurse or doctor working 100% in IPC) available? Choose one answer	☐ No, only a part-time IPC professional available	25
	Yes, one per > 250 bods	5
	☐ Yes, one per ± 250 beds	10
4. Does the IPC team or focal person have dedicated time for IPC	□ No	0
activities?	☐ Yes	10
5. Does the IPC team include both doctors and nurses?	□ No	.0
	□ vei	10
6. Do you have an IPC committee actively supporting the IPC team?	□ No	0
	☐ Yes	10.
7. Are any of the following professional groups represented/included in	n the iPC committee?	
Senior facility leadership (for example, administrative director, chief executive officer (CEO), medical director)	□ No	0
	□ Ves	5
Senior climical staff (for example, physician, nurse)	□ No	n
	☐ Yes	2.5
acility management (for example, biosafety, waste, and those tasked	□ No	D
with addressing water, sanitation, and hygiene (WASH)	□ Yes	25
8. Do you have clearly defined IPC objectives (that is, in specific	□ No.	0
critical areas)? Choose one answer	Yes, IPC objectives only	2.5
	☐ Yes, IPC objectives <u>and</u> measurable outcome indicators (that is, adequate measures for improvement)	5
	Yes, IPC objectives, measurable outcome indicators and set future targets	10
9. Does the senior facility leadership show clear commitment and sup	port for the IPC programme:	
By an allocated budget specifically for the IPC programme (that is, covering IPC activities, including salanes)?	□ No	n
covering in C activities, rocutaing sauries)?	☐ Yes	3
By demonstrable support for IPC objectives and indicators within the lacility (for example, at executive level meetings, executive rounds.	□ No.	0
participation in morbidity and mortality meetings)?	□ Yes	5
10. Does your facility have microbiological laboratory support	□No	0
(either present on or off site) for routine day-to-day use? Choose one answer	Yes, but not delivering results reliably threely and of sufficient quality)	5
	Yes, and delivering results reliably (timely and of sufficient	10

a PC programme amount from course and other course in the description of providing and providing and another course and advantage and providing and another course from the providing and another course another course and another course and another course and another course another course and another course another course another course another course and another course ano

a PC politica del Company State general relacione luminostros (PC position

I AN PC COMMITTEE IS A PRESENCE OF THE PERSONNEL CONTROL OF THE PERSONNEL OF THE PERSONNEL

Question	Answer	Score
Does your facility have the expertise (in IPC and/or infectious diseases) for developing or adapting guidelines?	□ No	0
	☐ Yes	7.5
2. Does your facility have guidelines available for:		
	□ No	0
Standard precautions?	☐ Yes	2.5
	□ No	0
Hand hygiene?	☐ Yes	2.5
	□ No	0
ansmission-based precautions?		25
Outbreak management and preparedness?		0
		2.5
	□ No	0
revention of surgical site infection F		2.5
Prevention of vascular catheter-associated bloodstream infections?	□ No	0
	☐ Yes	2.5
Prevention of hospital-acquired pneumonia ([HAP]: all types of HAP including (but not exclusively) ventilator-associated	□ No	0
pneumonia)?	☐ Yes	2.5
	□ No	0
Prevention of catheter-associated unnary tract infections?	☐ Yes	2.5
	□ No	0
Prevention of transmission of multidrug-resistant (MDR) pathogens?	☐ Yes	2.5
	□No	0
Disinfection and sterilization?	☐ Yes	2.5
	□No	0
lealth care worker protection and safety*	☐ Yes	2.5
	□No	0
njection safety?	☐ Yes	2.5
	□ No	0
Naste management?	☐ Yes	2.5
	□ No	0
Antibiotic stewardship?"	☐ Yes	2.5

Transmission based from an instruction to Standard Processions for purely and may be in legislar or colorized with person infectious agents for which additional presentation are record to prevent infection the surface and the following from the following from the following for the following following for the following for the following for the following following

If the surgical interventions we undertaken at your facility, choose arrows "Ses"

a include agonds of improving working conditions, detection of populational detection, health numeritance of workers, are employment accessing and visconstrons.

Refer to the appropriate use of anti-models to improve partial outcomes while never directly development and sorted of resistance. More information can be found and in the mind of the development of the control of the provider of the control of the control



Subtotal score		/100
	☐ Yes	10
8. Do you regularly monitor the implementation of at least some of the IPC guidelines in your facility?	□ No	0
	☐ Yes	10
7. Do health care workers receive specific training related to new or updated IPC guidelines introduced in the facility?	□ No	0
in the development and adaptation of the IPC guidelines in addition to IPC personnel?	☐ Yes	7.5
6. Are relevant stakeholders (for example, lead doctors and nurses, hospital managers, quality management) involved		0
fition to IPC personnel?		10
5. Are frontline health care workers involved in both planning and executing the implementation of IPC guidelines	□ No	o.
standards?	☐ Yes	10
4. Is implementation of the guidelines adapted according to the local needs and resources while maintaining key IPC	□ No	0
	☐ Yes	10
3. Are the guidelines in your facility consistent with national/international guidelines (if they exist)?	□ No	9

In PS have confully review publishes to print the activities according to medium discourse while mandaming less PS grandeds





Question	Answer	Score
Are there personnel with the IPC expertise (in IPC and/or infectious diseases) to lead IPC training?	□ No.	0
	☐ Yes	10
Are there additional non-IPC personnel with adequate skills to serve as trainers and mentors (for example, link nurses or doctors,	□ No	0
champions)? Choose one answer	☐ Yes.	10
How frequently do health care workers receive training regarding IPC in your facility? Choose one answer	☐ Neves or randy.	ò
	☐ New employee orientation only for health care workers	5
	New employee chentation and regular (at least annually) IPC training for health-cure workers affered but not mandatory	10
	New employee orientation and regular (at least annually) mandatory IPC training for all health care workers	15
How frequently do cleaners and other personnel directly involved in patient care receive training regarding IPC in your facility? Choose one answer	☐ Never of rarely	0
	☐ New employee orientation only for other personnel	5
	New employee orientation and regular (at least annually) training for other personnel offered but not mandatory	10
	New employee orientation and regular (at least annually) mundatory IPC training for other personnel	15
5. Does administrative and managerial staff receive general training	□ No	0
regarding IPC in your facility? Choose one answer	□ ∀ex	â
6. How are health care workers and other personnel trained?	☐ No training available	D
Choose one answer	Using written information and/or oral instruction and/or e-learning only	5
	☐ Includes additional interactive training sessions (for example, simulation and/or bedside training)	10
7. Are there periodic evaluations of the effectiveness of training	□ No	0
programmes (for example, hand hygiene audits, other checks on knowledge)?	☐ Yes, but not regularly	5
Choose one answer	☐ Yes, regularly (at least annually).	10
5. Is IPC training integrated in the clinical practice and training of	□ No	0
other specialties (for example, training of surgeons involves aspects of IPC)?	☐ Yes, in some disciplines	5
Choose one answer	☐ Yes; in all disciplines	10
Is there specific IPC training for patients or family members to minimize the potential for health care-associated infections	□ No.	0
(for example, immunosuppressed patients, patients with invasive devices, patients with multidrug-resistant infections)?	☐ Yest	ŝ
10. Is ongoing development/education offered for IPC staff	□ No	Ð
(for example, by regularly attending conferences, courses)?		_



Question	Answer	Score
Organization of surveillance		
Is surveillance a defined component of your IPC programme?	□ No	0
	☐ Ves	5
Do you have personnel responsible for surveillance activities?	□ No	.0
	□ /ves	5
Have the professionals responsible for surveillance activities been trained in basic epidemiology, surveillance and IPC (that is,	□ No	0
capacity to oversee surveillance methods, data management and interpretation)?	☐ Yes	5
4. Do you have informatics/IT support to conduct your surveillance	□ No	0
(for example, equipment, mobile technologies, electronic health records)?	☐ Yes	5.
Priorities for surveillance - defined according to the scope of care		
Do you go through a prioritization exercise to determine the HAIs to be targeted for surveillance according to the local context (that is, identifying infections that are major causes of morbidity and mortality in the facility)?	□ No	Û
	☐ Yes	5
6. In your facility is surveillance conducted for:		
Surgical site infections ^{3/2}	□ No	0.
	☐ Wes	2.5
Device-associated infections (for example, catheter-associated unnary tract infections, central line-associated bloodstream infections, peripheral-line associated bloodstream infections, ventilator-associated preumonia)?	☐ No	0
	☐ Ves	2.5.
Clinically-defined infections (for example, definations based only on	□ No	D
clinical signs or symptoms in the absence of microbiological testing)?	□ ves	2.5
Colonization or infections caused by multidrug resistant 1 pathogens	□ No	0
according to your local epidemiological situation?	□ Ves	2.5
ocal priority epidemic prone infections (for example, norovirus,	□ No	0
nfluenza, tuberculosis [TB], severe acute respiratory syndrome [SARS], Ebola, Lassa fever)?	☐ yes	7.5
Infections in vulnerable populations (for example, neonates, intensive care unit, immunocompromised, burn patients) ^{71,8}	□ No	o o
	☐ Yes	25
Infections that may affect health care workers in clinical, laboratory, or other settings (for example, hepatitis 8 or C. human immunodeficiency virus [HIV], influenza)?	□ No	0
	☐ Yes	2.6
7. Do you regularly evaluate if your surveillance is in line with the	□ No	0
current needs and priorities of your facility?	□ ves	5

If A promitation exercise around be undertaken to determine which HAIs to beget for purely according to the best portion of the undertaken according to avenue and a promitation and Common Programmes at Management and Common Programmes and Common Programmes at Management and Common

II if no surpoil elementors are understance your facility choson amount "Visit."

is Multimaple stated Non-suppositivity to at least one agent in three or more artimicolous nategories.

is if varieties patient populations are not triated at your facility choose traver "Yes".

Methoda of surveillance		
Do you use reliable surveillance case definitions (defined numerator and denominator according to international definitions	□ No	Ú
e.g. CDC NHSN/ECDC or if adapted, through an evidence-based adaptation process and expert consultation?	□ Yes	5
Do you use standardized data collection methods (for example, active prospective surveillance) according to international surveillance protocols (for example, CDC NHSN/ECDC) or if	□ No	Đ
adapted, through an evidence-based adaptation process and expert consultation?	☐ Yes.	5
Do you have processes in place to regularly review data quality for example, assessment of case report forms, review	□ No	0
of microbiology results, denominator determination, etc.)?	☐ Yes	В
Do you have adequate microbiology and laboratory capacity	□No	0
o support surveillance? Thoose one answer	☐ Yes, can differentiate gram-positive/negative-strains but cannot identify pathogens	2.5
	☐ Yes, can reliably identify pathogens (for example, solate identification) in a timely manner	1
	Ves. can reliably identify pathogens and antimicrobial drug resistance patterns (that is, susceptibilities) in a timely manner	ig
nformation analysis and dissemination/data use, linkage, and govern	nance	
2. Are surveillance data used to make tailored unit/facility-based	□ No.	0
plans for the improvement of IPC practices?	□ Yes	5
3. Do you analyze antimicrobial drug resistance on a regular basis	□ No	0
(for example, quarterly/half-yearly/annually)?	☐ Yes	5
4. Do you regularly (for example, quarterly/half-yearly/annually) fee	dback up-to-date surveillance information to:	
Frontline health care workers (doctors/nurses)?	□ No	0
	□ Yes	25
Clinical leaders/heads of department	□ No	.0
	☐ Yes	25
PC committee	□ No	0
	□ Yes	2.5
ion-clinical management/administration (chief executive officer/chief	□ No	0
inancyl(officer)?	☐ Yes	2.5
5. How do you feedback up-to-date surveillance information? at least annually) Triogse one answer	☐ No feierthiack	ė
	☐ By written/oral information only	25
	By presentation and inferactive problem-orientated solution finding	73
Subtotal score		/10

United States Centers for Decimie Control and Prevention (CEC) (about the arthur Safety harrives (PPCH) (https://www.cde.gov.nten/asies.html accessed (13 April 2018).

Fundam Center for Decimie Prevention and Control (CEC) (https://www.cde.europa.euro/about us/partnerships/and-networks/dessate and laboratory networks final accessed (13 April 2018).

PART 2: FACILITY LEVEL AMS PROGRAM

Table 16: Facility level AMS program assessment tool

Assessment of activities in the	of Antimicrobial Stewardship Program (AMSP) ne facility	at facility	Comment
Leadership support	Does your facility have a formal, written statement of support from facility administration that supports efforts to improve antibiotic use (antibiotic stewardship)?		
	Does your facility receive any budgeted financial support for antibiotic stewardship activities (e.g., support for salary, training, or IT support)?	Д	
Accountability	Is a staff member directly responsible for coordination and program outcomes of stewardship activities at your facility?		
	Does your institution have a committee to review processes and outcomes of the stewardship program?	J	
	Does your antibiotic stewardship committee meet at least once every 6 months? Are the minutes of the stewardship committee communicated to all stakeholders?	ш	
Key support for the antibiotic stewardship program	Does any of the staff below participate in the stewardship program to improve antibiotic use? Tick as appropriate •Clinical pharmacist or other pharmacy staff •Clinical pharmacologist or pharmacology staff •ID physician (specialists in medicine, paediatrics and surgery who deal with pertinent infections) •Infection prevention and control team/focal persons •Q u a lity improvement staff •Clinical microbiologist		
M	•IT department staff (not on committee but they help us as needed) •Clinical departments heads (not heads, but members.		
	All the proceedings are communicated to the heads and they preside over the meeting when any of their units are being audited)		
2	Hospital administration staff		